The Board has considered and approved the appointment of Mrs. Padmaja Kalyani Sadhanala as an Additional director, Non Executive and Non Independent Director and Mr. Revoor Ramachandra ....
Price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Venmax Drugs and Pharmaceuticals announced the outcome of its board meeting held on March 30, 2026. The board approved the appointment of Mrs. Padmaja Kalyani Sadhanala as an Additional Director (Non-Executive and Non-Independent), who is the spouse of the company's Managing Director and holds a postgraduate degree in Genetics with over 20 years of pharma industry experience. Additionally, Mr. Revoor Ramachandra was appointed as an Additional Non-Executive and Independent Director for a five-year term; he brings over 42 years of experience in defence, aerospace, and automotive sectors. Both appointments are subject to shareholder approval at the next general meeting. No managerial remuneration was proposed for either appointee.
The appointment of a promoter family member to the board reinforces family control of the company, which is common in small-cap pharma firms but may concern governance-focused investors. Adding an experienced independent director with a strong industrial background could strengthen board oversight.